BP
BigPeptideList

AOD-9604

Compoundable (Rx)

Fat Loss Peptides · Metabolic

AOD-9604 is a modified fragment (amino acids 177-191) of human growth hormone specifically designed for fat loss.

What is AOD-9604?

AOD-9604 is a modified fragment (amino acids 177-191) of human growth hormone specifically designed for fat loss. It retains the fat-reducing action of HGH without the growth-promoting effects or blood sugar impacts, making it a targeted approach to fat metabolism.

Also known as: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

How Does AOD-9604 Work?

Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-reducing fragment of growth hormone. Activates beta-3 adrenergic receptors in fat tissue. Does not affect IGF-1 levels or insulin sensitivity, unlike full HGH.

What is AOD-9604 Used For?

  • Fat loss
  • Metabolic support
  • Body composition

Potential Side Effects

  • Injection site irritation
  • Headache (mild)
  • Flu-like symptoms (rare)

Contraindications

  • Pregnancy
  • Children
  • Active cancer

FDA Legal Status

United States — FDA

Compoundable (Rx)

Category 1 (restored 2026)

Related Peptides

MOTS-c

Compoundable (Rx)

Metabolic Peptides

MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene. It functions as an exercise mimetic, activat...

Semaglutide

FDA Approved

GLP-1 Receptor Agonists

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes management and chronic weight...

Frequently Asked Questions

Does AOD-9604 really work for fat loss?
Clinical evidence is mixed. Early studies showed promise for fat reduction without HGH side effects. A Phase 2b trial showed modest improvements. It's less effective than GLP-1 agonists but may have fewer side effects. Evidence rating is C — more research needed.
How is AOD-9604 different from HGH?
AOD-9604 is just the fat-burning fragment of HGH (amino acids 177-191). It promotes fat breakdown without the muscle-building, blood-sugar-altering, or organ-growth effects of full HGH. This means targeted fat loss with fewer systemic effects.

Quick Facts

Legal Status (USA)
Compoundable (Rx)
FDA Category
Category 1 (restored 2026)
Evidence Rating
CPreliminary Evidence (Mostly Preclinical)
Class / Subclass
Fat Loss Peptides / Metabolic
Administration
subcutaneous, oral
Typical Dosage
250-500mcg daily
Half-Life
~2-3 hours
Year Discovered
1990

Sources

PubMed 11713213

Last updated: 2026-04-01

Sources & references

Primary sources used for the dosing, mechanism, side-effect, and regulatory claims on this page. Verify time-sensitive information (regulatory status, prescribing details) on the source before relying on it for medical decisions. See our disclaimer.

  1. PubMed PMID 11713213 — peer-reviewed primary literature on AOD-9604.
  2. FDA Federal Register — official notice record for FDA regulatory actions and Category 1 / 503A bulk-substance updates.